加载中
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
收盘时
US$5.87
−US$0.25 · -4.08%
盘后
US$5.87
US$0.00 · 0.00%
10月13日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
日内区间
当前US$5.87
52周区间
当前US$5.87
盘中时间采用ET。市场数据可能有所延迟。
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
日内区间
当前US$5.87
52周区间
当前US$5.87
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 644万 USD | 2962.1万 USD | 4680.3万 USD | 1.41亿 USD | 2.35亿 USD |
| 销货成本 | 55.6万 USD | 1556.1万 USD | 396.2万 USD | 2028万 USD | 4.49亿 USD |
| 毛利 | 588.4万 USD | 1406万 USD | 4284.1万 USD | 1.2亿 USD | −2.14亿 USD |
| 研究与开发 | 2351.7万 USD | 9569.2万 USD | 2.66亿 USD | 2.97亿 USD | 3.87亿 USD |
| 销售、一般及管理费用 | 2770.9万 USD | 4933万 USD | 8648.3万 USD | 1.25亿 USD | — |
| 营业费用 | 5177.9万 USD | 1.64亿 USD | 3.66亿 USD | 4.21亿 USD | 7464.7万 USD |
| 利息收入 | 294.3万 USD | 529.6万 USD | 759.4万 USD | 759.6万 USD | — |
| 利息支出 | 875.9万 USD | 824.7万 USD | 809.5万 USD | 144万 USD | 107.5万 USD |
| 折旧和摊销 | 74.8万 USD | 269.2万 USD | 993万 USD | 1060.4万 USD | 1480.9万 USD |
| 营业利润 | −4589.5万 USD | −1.5亿 USD | −3.23亿 USD | −3.01亿 USD | −2.89亿 USD |
| 净利润 | 1.83亿 USD | −4757.9万 USD | −2.84亿 USD | −2.94亿 USD | −2.9亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$28.00
上涨空间 377.00%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年6月17日 | 1:25 | — | — |
已生效 2025年6月17日
1:25
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
